MG
KALV

Marex Group’s KalVista Pharmaceuticals KALV Stock Holding History

Marex Group’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$403K Buy
+20,000
New +$322K ﹤0.01% 686

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marex Group's KALV Position: Q1 2026 in Review

Marex Group opened a new position in KalVista Pharmaceuticals (KALV) in Q1 2026: 20,000 shares worth $403K. The stake represents ﹤0.01% of the portfolio and ranks #686 among its holdings.

183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Marex Group held 20,000 shares of KalVista Pharmaceuticals worth $403K as of Q1 2026.
  • KalVista Pharmaceuticals was a new Marex Group position in Q1 2026.
  • KalVista Pharmaceuticals made up ﹤0.01% of Marex Group's portfolio in Q1 2026, its #686 holding.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Marex Group's 13F filing for Q1 2026, filed 13 May 2026.